| Biomarker ID | 132 |
| PMID | 17764114 |
| Year | 2008 |
| Biomarker | PTGS2 |
| Biomarker Basis | Concentration Based(ng/ml) |
| Biomolecule | Other |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa [(Mean Values) PCa: 85.95; Healthy Individuals: 10.88] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Selenium pathway, C-Myb transcription factor network,VEGF signaling pathway,Leishmaniasis,Prostaglandin biosynthesis and regulation |
| Experiment | Prostate Cancer (PCa) Vs Healthy Individuals |
| Type of Biomarker | Diagnostic |
| Cohort | Serum of 216 patients was evaluated. 168 having PCA, 5 incidental PCA, 42 Benign Prostatic Hyperplasia and 11 healthy patients. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | P<0.0001 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PTGS2 |